58
Views
1
CrossRef citations to date
0
Altmetric
Research Article

Chemical and anticancer activity studies for some 3-chloro-3-chlorosulfenyl-4′-methylspiro[chroman-2,1′-cyclohexane]-4-ones

, , , , &
Pages 970-977 | Received 02 Mar 2021, Accepted 21 Jun 2021, Published online: 05 Jul 2021
 

Abstract

3-Chloro-3-chlorosulfenyl-4′-methylspiro[chroman-2,1′-cyclohexane]-4-one (4) was prepared from the reaction of spiro 4′-methylcyclohexan-1′,2-chroman-4-one (3) with thionyl chloride according to reported method. Furthermore, treatment of compound 4 with potassium iodide gave 1,2-bis (3-chloro-4′-methylspirochroman-2,1′-cyclohexyl-4-one)disulfane (6) in addition to 4,4‴-dimethyltrispiro[cyclohexane-1,2′-chroman-3′,2″-2H-chromeno[3,4-e][1,3,4]-oxadithiin-5″,1‴-cyclohexan]-4′-one (5). The formation of compound 5 could be presumably explained via the formation of unstable intermediate oxo-thioketone A. The formation of the latter intermediate A was confirmed chemically through the thermal reaction of compound 5, or compound 6 with 1,3-homodiene such as: 1,3-cyclohexadiene, isoprene, and 2,3-dimethyl-1,3-butadiene to afford the products 7–9, respectively. The chemical structures of the newly prepared compounds were confirmed by spectroscopic methods (IR, 1H & 13C NMR, and MS). The synthesized compounds were evaluated against lung (A549), prostate (PC3), pancreatic (PACA2), and breast (MDA) cancer cell lines. Compound 3 exhibited prominent cytotoxicity against A549, PC3, and PACA2 cancer cell lines with IC50 values from 12.4 to 16.1 µM, which was comparable or superior to the reference drug (Doxorubicin). Compounds 7–9 showed better cytotoxicity against breast (MDA) cancer cell line than the reference drug (Doxorubicin).

Graphical Abstract

Additional information

Funding

This project is funded by National Research Centre, Dokki, Giza, Egypt [Project Number: 12010101].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.